E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 8.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10033371 |
E.1.2 | Term | Pain |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of the study is to evaluate the safety profile of CG5503 base IR 50 mg or 100 mg taken every 4 to 6 hours as needed over the long term exposure of 90 days |
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives include: • Estimate the relative safety profile of CG5503 and oxycodone subjects • Evaluation of the symptoms of withdrawal from opioids following discontinuation of study drug using the Clinical Opioid Withdrawal Score (COWS) and the Subjective Opioid Withdrawal Score (SOWS) questionnaires. • Evaluation of symptoms related to GI tolerability (i.e., constipation and vomiting) using the Patient Assessment of Constipation Symptoms (PAC SYM), a single question regarding vomiting, and a sleep assessment • Assessment of pain intensity (PI) over the 90-day study period • Assessment of the Patient Global Impression of Change (PGIC) as recorded at the end of treatment |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Subjects must satisfy the following criteria to be enrolled in the study: • Men or women ≥18 years of age, inclusive • Must be ambulatory, not planning surgery for the duration of the study and able to complete all study related procedures and requirements throughout the trial period • Women must be postmenopausal, surgically sterile, or practicing or agree to practice an effective method of birth control if they are sexually active before entry and throughout the study (effective methods of birth control include prescription hormonal contraceptives, intrauterine devices, double barrier method, and male partner sterilization). Women of childbearing potential must have a negative serum ß-human chorionic gonadotropin (ß-hCG) pregnancy test at screening and a negative urine pregnancy test on Day 1 • Subjects must use satisfactory contraception from the first dose of study drug up to 7 days after the last dose of study drug • A clinical diagnosis of one of the following: - Low back pain of non-malignant origin for at least 3 months - Osteoarthritis of the knee or hip for at least 3 months • Require daily doses of analgesia medication for chronic pain that is consistent with or makes them candidates for treatment at Step 2 or higher of the World Health Organization (WHO) Pain Relief Ladder. The regular daily analgesia may consist of NSAIDs or opioids taken for at least the 30 days before screening, alone or in combination, to control chronic pain. Opioid use must be no more than 80 mg morphine equivalents per day • Post-washout baseline PI score ≥4 on an 11-point numerical rating scale • The subject has willingly signed an informed consent document indicating that he or she understands the purpose of and procedures required in the study, and before undergoing any study procedure |
|
E.4 | Principal exclusion criteria |
Potential subjects who meet any of the following criteria will be excluded from participating in the study: • Women who plan to become pregnant during the study, or who are breastfeeding • Received an experimental drug or used an experimental medical device within 30 days before screening or has participated in a previous study of CG5503 • History of malignancy within the past 2 years, with the exception of basal cell carcinoma • Contraindications to, history of allergy to, or hypersensitivity to CG5503, oxycodone, hydromorphone, morphine, or fentanyl, or their excipients • Systemic steroid therapy, excluding inhalers or topical steroids, within 3 months before screening • Injectable hyaluronic acid within 6 months before screening • Currently treated with monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs) or neuroleptics. Selective serotonin reuptake inhibitor (SSRI) and serotonin norepinephrine reuptake inhibitor (SNRIs) treatments are allowed if taken for at least 30 days before the screening period of the study at an unchanged dose • History of chronic hepatitis B or C, or HIV 1 and 2, or presence of active hepatitis B or C within the past 3 months before screening • Uncontrolled hypertension (systolic blood pressure greater than 160 mmHg or diastolic blood pressure greater than 95 mmHg) • Uncontrolled or poorly controlled post-traumatic stress disorder (PTSD), generalized anxiety disorder (GAD), depression, psychiatric or other significant medical condition(s) • History of seizure disorder or epilepsy suggested by the presence of any of the following: - Mild or moderate traumatic brain injury, stroke, transient ischemic attack, or brain neoplasm within 1 year of screening - Severe traumatic brain injury, episode(s) of unconsciousness or post-traumatic amnesia of more than 24 hours duration within 15 years of screening • History of alcohol and/or drug abuse • Concomitant autoimmune inflammatory condition • Acute crystal-induced arthropathy within the 6 months before screening • Laboratory values reflecting moderate to severe renal insufficiency or hepatic impairment based on alanine aminotransferase (ALT) or aspartate aminotransferase (AST) values greater than 3 times the upper limit of normal (ULN) • Pending litigation due to a history of chronic pain or disability • Clinically significant disease that in the investigator’s opinion may affect efficacy or safety assessment • Employees of the investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, as well as family members of the employees or the investigator. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Safety: • Collection of adverse events • Changes in clinical laboratory, ECG vital signs and findings on physical examinations • Patient assessment of constipation using the PAC-SYM, assessment of vomiting and assessment of sleep • Symptoms of opioid withdrawal using COWS and SOWS scales Efficacy: • Changes in Pain Intensity Scale versus baseline • Patient’s Global Assessment of Change versus baseline |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | Information not present in EudraCT |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 11 |
E.8.5 | The trial involves multiple Member States | Information not present in EudraCT |
E.8.5.1 | Number of sites anticipated in the EEA | 11 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The study is considered completed with the last visit of the last subject undergoing the study. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 7 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |